Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial

NCT00988429 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT00988429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00988429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 3
Overall status
Completed
Start date
December 2, 2008
Completion date
January 12, 2012
Enrollment
653 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

partial epilepsy